The primary efficacy outcome of RE-COVER indicated that dabigatran was as effective (or, in methodological terms, was non-inferior) to warfarin for the prevention of recurrent venous thromboembolism or related mortality (Figure 12).[7]  The Figure show data out to approximately 6 months, when the recurrent rate was around 2.5% and similar in both groups.  Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.